- Home
- SSBK vs PRQR Comparison
SSBK vs PRQR Comparison
Compare SSBK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- PRQR
- Stock Information
- Founded
- SSBK 2007
- PRQR 2012
- Country
- SSBK United States
- PRQR Netherlands
- Employees
- SSBK N/A
- PRQR N/A
- Industry
- SSBK Commercial Banks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- PRQR Health Care
- Exchange
- SSBK Nasdaq
- PRQR Nasdaq
- Market Cap
- SSBK 330.0M
- PRQR 309.5M
- IPO Year
- SSBK 2021
- PRQR 2014
- Fundamental
- Price
- SSBK $31.97
- PRQR $1.64
- Analyst Decision
- SSBK Buy
- PRQR Strong Buy
- Analyst Count
- SSBK 1
- PRQR 6
- Target Price
- SSBK $36.00
- PRQR $8.50
- AVG Volume (30 Days)
- SSBK 13.4K
- PRQR 449.0K
- Earning Date
- SSBK 04-21-2025
- PRQR 03-13-2025
- Dividend Yield
- SSBK 1.13%
- PRQR N/A
- EPS Growth
- SSBK 3.86
- PRQR N/A
- EPS
- SSBK 3.67
- PRQR N/A
- Revenue
- SSBK $94,140,000.00
- PRQR $20,235,014.00
- Revenue This Year
- SSBK $19.13
- PRQR $39.44
- Revenue Next Year
- SSBK $7.78
- PRQR N/A
- P/E Ratio
- SSBK $8.73
- PRQR N/A
- Revenue Growth
- SSBK 13.56
- PRQR 196.41
- 52 Week Low
- SSBK $22.13
- PRQR $1.61
- 52 Week High
- SSBK $39.16
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- SSBK 48.10
- PRQR 26.73
- Support Level
- SSBK $31.49
- PRQR $1.78
- Resistance Level
- SSBK $32.50
- PRQR $1.87
- Average True Range (ATR)
- SSBK 0.79
- PRQR 0.13
- MACD
- SSBK 0.07
- PRQR -0.04
- Stochastic Oscillator
- SSBK 58.60
- PRQR 1.22
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.